Unknown

Dataset Information

0

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.

ABSTRACT:

SUBMITTER: Reville PK 

PROVIDER: S-EPMC7969746 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
| S-EPMC6397669 | biostudies-literature
Unknown High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study.
| S-EPMC9616883 | biostudies-literature
Unknown Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
| S-EPMC8500663 | biostudies-literature
Unknown CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial.
| S-EPMC9808483 | biostudies-literature
Unknown A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer.
| S-EPMC9013329 | biostudies-literature
Unknown Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
| S-EPMC6172068 | biostudies-literature
Unknown Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial.
| S-EPMC10626224 | biostudies-literature
Unknown Obinutuzumab induction and maintenance in patients with Waldenstrom macroglobulinaemia: an open-label, single-arm phase 2 study.
| S-EPMC12318314 | biostudies-literature
Transcriptomics Disulfiram Plus Nivolumab in Patients with Advanced Gastric Cancer: An Open-Label Phase I Trial
2022-11-27 | GSE189926 | GEO
Unknown Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
| S-EPMC8130026 | biostudies-literature